AMLN Financial Facts

Net product sales: 150.59M
Total costs and expenses: 208.02M
See Full Income Statement

Total current liabilities: 290.21M
Deferred revenue, current portion: 7.5M
See Full Balance Sheet

Amylin Pharmaceuticals, Inc. (AMLN) Earnings

  |   Expand Research on AMLN
Next EPS Date N/A EPS Growth Rate N/A
Average EPS % Beat Rate -945.0% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS +0.5% Normal Earnings Time N/A
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
2/6/12 Q411 -$3.15-$0.08 -$3.07$164.9M$163.64M N/A Details
7/26/11 Q211 -$0.21-$0.18 -$0.03$158.07M$157.72M N/A Details
10/19/11 Q311 -$0.07-$0.15 +$0.08$155.1M$166.39M N/A Details
4/26/12 Q112 -$0.23-$0.29 +$0.06$153.7M$161.66M N/A Details
4/18/11 Q111 -$0.24-$0.23 -$0.01$152.7M$156.73M N/A Details
11/4/10 Q310 -$0.35-$0.35 $0.00N/AN/A N/A Details